We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Assessment of SGLT2 inhibitors' safety and discontinuation causes in patients with advanced chronic kidney disease: insights from a real-world data analysis.
- Authors
Perrin, Peggy; Muller, Clotilde; Dimitrov, Yves; Chantrel, Francois; Heitz, Marie; Woerly, Amandine; Bazin, Dorothée; Faller, Anne-Laure; Krummel, Thierry; Hannedouche, Thierry
- Abstract
This article examines the use of sodium-glucose cotransporter 2 inhibitors (SGLT2i) in patients with advanced chronic kidney disease (CKD). The study analyzed real-world data from 271 patients and found that 10.3% discontinued SGLT2i use at 6 months, primarily due to a decline in estimated glomerular filtration rate (eGFR). Patients who discontinued SGLT2i experienced a steeper decline in eGFR compared to those who continued treatment. The study suggests that nephrologists should manage the underlying causes of eGFR decline and consider reintroducing therapy.
- Subjects
SODIUM-glucose cotransporter 2 inhibitors; TRANSIENT ischemic attack; URINARY tract infections; HEMORRHAGIC stroke; DIASTOLIC blood pressure; HEART failure; DIABETIC nephropathies
- Publication
Clinical Kidney Journal, 2024, Vol 17, Issue 7, p1
- ISSN
2048-8505
- Publication type
Article
- DOI
10.1093/ckj/sfae169